A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.AstraZeneca said it is doubling down on its investment in its U.

AstraZeneca plans a new investment of $2 billion in the U.S., one of the first major foreign companies to shift spending to the country after Donald Trump’s election win.The decision comes in response to the U.

AstraZeneca AZN0.05%increase; green up pointing triangle said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to commit significant new spending to the country after Donald Trump’s election win.

AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to invest $3.5 billion in the US business by the end of 2026.